-
-
NHG-werkgroep Verdachte huidafwijkingen. NHG-Standaard Verdachte huidafwijkingen. Huisarts Wet 2017;60(6):276-90.
-
-
Argenziano G, Longo C, Cameron A, et al. Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma. Br J Dermatol. 2011;165(6):1251-1255.
-
Menzies S, Moloney FJ, Byth K, et al. Dermoscopic evaluation of nodular melanoma. JAMA Dermatol. 2013;149(6):699-709.
-
Pizzichetta MA, Kittler H, Stanganelli I, et al., Pigmented nodular melanoma: the predictive value of dermoscopic features using multivariate analysis. Br J Dermatol. 2015;173(1):106-14.
-
Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16(6):345-58.
-
Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005;41(1):28-44.
-
Van Doorn R. Genetica en diagnostiek van familiair melanoom. NTvDV 2016;26(11):651-54.
-
El Ghissassi F, Bann R, Starif K, et al. A review of human carcinogens – Part D: radiation. Lancet Oncol 2009; 10(8):751-752.
-
Moan J, Grigalavicius M, Baturaite Z, et al. The relationship between UV exposure and incidence of skin cancer. Photodermatol Photoimmunol Photomed 2015;31(1):26-35.
-
International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer. 2007;120(5):1116-22.
-
-
-
-
Nederlandse Vereniging voor Dermatologie en Venereologie. www.nvdv.nl. Geraadpleegd augustus 2018.
-
Walter FM, Prevost AT, Vasconcelos J, et al. Using the 7-point checklist as a diagnostic aid for pigmented skin lesions in general practice: a diagnostic validation study. Br J Gen Pract. 2013;63(610):e345-53.
-
Mayer J. Systematic review of the diagnostic accuracy of dermatoscopy in detecting malignant melanoma. Medical journal of Australia 1997; 167(4):206-210.
-
Bafounta ML, Beauchet A, Aegerter P, et al. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma?: Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Archives of dermatology 2001; 137(10):1343-1350.
-
Kittler H, Pehamberger H, Wolff K, et al. Diagnostic accuracy of dermoscopy. The lancet oncology 2002; 3(3):159-165.
-
Vestergaard ME, Macaskill PHPM, Holt PE, et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta‐analysis of studies performed in a clinical setting. British Journal of Dermatology 2008; 159(3):669-676.
-
Secker LJ, Bergman W, Kukutsch, NA. Dermatoscopie in de huisartspraktijk 1. Huisarts Wet 2015;1:38-41.
-
Balch CM, Gerschenwald JE, Soong SJ et al. Final version of 2009 AJCC Melanoma staging and classification. J. Clin. Oncol. 2009; 27:6199-6206.
-
Van Zeijl MCT, van den Eertwegh AJM, Wouters MWJM et al. Recente behandelresultaten van uitgezaaid melanoom. Gegevens uit de Dutch Melanoma Treatment Registry. Ned Tijdschr Geneeskd 2018;162:D2420.
-
Werkgroep Immunotherapie Nederland voor Oncologie (WIN-O). Advies van Werkgroep Melanoom WIN-O. Behandeling van het gemetastaseerd melanoom anno 2016. Medische Oncologie 2016;32-34.
-
Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 2016; 375:1845-1855.
-
Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017;377(19):1813-1823.
-
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824-1835.
-
Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018; 378:1789-1801.
-
Ugurel S, Röhmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247-57.
-
Van Thienen JV. Uitbreiding behandelarsenaal vraagt om doelmatigheid. Ned Tijdschr Geneeskd 2018;162:D2647.
-
Hamid O, Robert C, Daud A, et al. 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018 (suppl; abstr 9516).
-
-
-
FTO Onderwerpen
FTO
